Skip to main content

About IDEAYA

IDEAYA is a precision medicine oncology company with deep research and development expertise in synthetic lethality. We are passionately pursuing the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA has a world-class team of leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development. Our Scientific Advisory Board (SAB) consists of academic and industry thought leaders including members of the National Academy of Sciences and the National Academy of Medicine.

O ur team has built a robust pipeline of potential first-in-class and/or best-in-class precision medicine therapeutics. We have target identification, validation and drug discovery research expertise, including in synthetic lethality – an emerging class of precision medicine targets. Our most advanced pipeline programs include darovasertib (IDE196), a clinical stage PKC inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations, IDE397, a clinical stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion, which represents approximately 15% of solid tumors, as well as IDE161, a clinical-stage PARG inhibitor for patients having tumors with homologous recombination deficiency (HRD).

Since inception, a key tenet of IDEAYA’s research has been to exploit the concept of synthetic lethality, an approach for indirectly targeting oncogenic pathways. Certain genetic alterations in cancer cells enable tumor proliferation, but also create vulnerabilities – which we target with our therapeutics. In cancer cells with such genetic alterations, pharmacological inhibition of the target can cause cell death. In normal cells, without such genetic alternations, the target inhibition can be non-lethal – creating a therapeutic window. Patients for our therapeutics are selected using molecular diagnostics to identify the genetic alternation or a related biomarker.

We are collaborating with Pfizer pursuant to a clinical trial collaboration and supply agreement on our darovasertib (PKC) program.  We are also collaborating with Amgen pursuant to a clinical trial collaboration and supply agreement on our IDE397 (MAT2A) program. We have established a strategic partnership with GlaxoSmithKline (GSK) on our Pol Theta and Werner Helicase synthetic lethality programs.

IDEAYA is headquartered in South San Francisco, California.

Management Team

Yujiro S. Hata

President and Chief Executive Officer

Darrin M. Beaupre, M.D., Ph.D.

Chief Medical Officer

Michael White, Ph.D.

Chief Scientific Officer

Paul A. Stone, J.D.

Chief Financial Officer

Paul A. Barsanti, Ph.D.

Chief Technology Officer

Jason S. Throne, J.D.

Chief Legal Officer

Andres Ruiz Briseno, C.P.A.

Senior Vice President, Head of Finance and Investor Relations

Mick O’Quigley

Senior Vice President, Development Operations

Matthew Maurer, M.D.

Vice President, Late Phase Oncology Clinical Development

Claire L. Neilan, Ph.D., DABT

Vice President, Preclinical Sciences

Jasgit Sachdev, M.D.

Vice President, Early Phase Oncology Clinical Development

Scientific Advisory Board

Frank McCormick, Ph.D.

SAB Chair | Professor, University of California at San Francisco

Karlene Cimprich, Ph.D.

Professor, Stanford University School of Medicine

Trey Ideker, Ph.D.

Professor, University California at San Diego

Kornelia Polyak, M.D., Ph.D.

Professor, Dana-Farber Cancer Institute, Harvard Medical School

William R. Sellers, M.D.

Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School

Elizabeth Swisher, M.D.

Professor, University of Washington

Board of Directors

Terry Rosen, Ph.D.

Chairman of the Board | Chief Executive Officer, Arcus Biosciences

Garret Hampton, Ph.D.

Director | President, Clinical Sequencing and Oncology, ThermoFisher Scientific

Yujiro S. Hata

Director | Chief Executive Officer, IDEAYA Biosciences

Susan L. Kelley, M.D.

Director | Former Chief Medical Officer of MMRC

Catherine Mackey, Ph.D.

Director | Former Senior Vice President of Pfizer Worldwide Research and Development

Scott Morrison

Director | Partner, Ernst & Young (retired)

Jeffrey Stein, Ph.D.

Director | President and Chief Executive Officer, Cidara Therapeutics

Wendy Yarno

Director | Former Executive Vice President and Chief Marketing Officer, Merck & Co.

Collaborations

University of California
San Diego

Synthetic Lethality Target Identification

Broad Institute

Biomarker and Translational Research

University of California
San Francisco

Biomarker and Translational Research

Novartis Institute for
Biomedical Research (NIBR)

IDE196 (PKC)

Yujiro S. Hata

President and Chief Executive Officer

Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In June 2015, he launched and incorporated IDEAYA Biosciences as its first employee and Chief Executive Officer and led the company’s IPO in May 2019 (NASDAQ: IDYA). From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, which he led through its acquisition by Bristol-Myers Squibb in April 2015, and then served as Chief Operating Officer at FLX Bio (renamed RAPT Therapeutics, NASDAQ: RAPT), a spinout of Flexus Biosciences. From 2010 to 2014, including through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Business Development, Senior Vice President, Business Development, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation and approval by the FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.

Yujiro obtained his M.B.A. at the University of Pennsylvania where he was a Henry J. Kaiser recipient and was awarded 1st prize at the 2nd Annual Wharton Business Plan competition out of 226 business plans. He obtained his B.A. in chemistry at Colorado College and did undergraduate studies in chemistry and biology at Oxford University. He served on the Board of Directors at Xencor (NASDAQ: XNCR) from 2015 to 2022 and serves on the Board of Directors at Enanta Pharmaceuticals (NASDAQ: ENTA) and as Board Member at the Moores Cancer Center at the University of California, San Diego.

LinkedIn

Darrin M. Beaupre, M.D., Ph.D.

Chief Medical Officer

Darrin is a Medical Oncologist and Hematologist with 16 years of industry experience in both early and late phase clinical development. He previously served as the Chief Medical Officer in Oncology at Biosplice overseeing the Oncology Research and Development Therapeutic area. Previous to this position he was Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, where he supervised the filing and execution of numerous INDs in broad platform areas including small molecules, large molecules, antibody drug conjugates, bispecifics, a CAR-T, and vaccines. Prior to joining Pfizer, he was Head of the Early Development, Immunotherapy, and Non-Hodgkin’s Lymphoma Therapeutic Areas at Pharmacyclics. There, he participated in the NDA filings of ibrutinib for mantle cell and marginal zone lymphoma, both of which achieved accelerated approvals. He also initiated Phase 2 and 3 trials testing ibrutinib in several Non-Hodgkin’s Lymphoma indications. Earlier in his career, Darrin served as a member of the Amgen early development group and was a Medical Director involved in filing multiple INDs. Linked to his translational medicine background, he also previously served as an Assistant Professor at the Moffit Cancer Center in the Department of Interdisciplinary Oncology. In addition to being awarded a Hollis Brownstein Research Grant, Darrin also received a Clinical Scholars in Oncology Award from the National Cancer Institute and was nominated as a “new scientist to watch” by the Leukemia Research Foundation. Dr. Beaupre completed his Medical Oncology and Hematology Fellowship and post-doctoral research training at the University of Miami Sylvester Cancer Center, where he was supported by an NIH K12 Award. He completed his MD and PhD in Cancer Biology at the University of Texas at Houston and MD Anderson Cancer Center, respectively, where he was a member of the MD PhD program.

Michael White, Ph.D.

Chief Scientific Officer

Mike is a discovery biologist with over two decades of R&D leadership experience in industry and academia. He has deep expertise in cell regulation, tumor biology, target discovery, technology development and drug discovery.

Mike transitioned from academia to the pharmaceutical industry in 2016 as CSO for Tumor Biology at Pfizer. There he led a cross-disciplinary group to build an oncology small-molecule pipeline focused on first-in-class therapies that intercept oncogenic signaling networks, modulate tumor/host interactions and promote productive anti-tumor immune responses. These efforts culminated in numerous INDs over a span of five years. Prior, Mike was Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center, and inaugural Director of the UTSW Cancer Intervention and Prevention Discovery training program. His appointments include the Hortense and Morton Sanger Professorship in Oncology, the Sherry Wigley Crow Cancer Research Endowed Chair, and the Grant A. Dove Distinguished Chair for Research in Oncology. In 2015, Mike received the inaugural National Institute of Cancer’s Outstanding Investigator Award. He has authored over 150 publications with over 22,000 citations.

Mike completed his postdoctoral training in cancer biology and signal transduction at Cold Spring Harbor Laboratories in New York. He received his Ph.D. in Biology from the University of North Carolina at Chapel Hill, and his B.Sc. (Hons) from the University of Iowa.

LinkedIn

Paul A. Stone, J.D.

Chief Financial Officer

Paul is a life science executive with over 20 years of legal, financial, and management experience. Paul was previously with 5AM Ventures for over nine years in various leadership capacities including as Partner, General Counsel, and Chief Operating Officer. Paul serves as a Board of Director of Scientist.Com and was a founding Director at Cidara (NASDAQ: CDTX), Homology (NASDAQ: FIXX), and IDEAYA (NASDAQ: IDYA), as well was a Board Observer at RareCyte and other companies. He also held early management and operating rolls at Cidara, Entrada, IDEAYA and Homology. Prior to joining 5AM, Paul was Senior Vice President and General Counsel at Ethos Pharmaceuticals, Senior Vice President, General Counsel and Chief Patent Counsel at Ilypsa (acquired by Amgen) and Vice President, Chief Patent Counsel at Symyx (IPO). He earlier served in roles at Boeing and Wisconsin Electric.

Paul earned a B.S. in Chemical Engineering, University of Wisconsin, Madison, after which he served as a U.S. Naval Officer on USS NIMITZ. He received a J.D. from University of Wisconsin Law School and practiced intellectual property law as a Patent Attorney at Senniger Powers. Paul taught patent law, trade secrets law and licensing as an adjunct professor at University of Missouri and Santa Clara University. He also served on the Board of Directors of a regional non-profit, Save the Bay.

LinkedIn

Paul A. Barsanti, Ph.D.

Chief Technology Officer

Paul brings over 20 years of drug discovery experience. He joined IDEAYA Biosciences as Vice President, Head of Drug Discovery in July 2019. Prior to that he was an Executive-in-Residence at 5AM Ventures where he was involved with several early seeded new companies. From 2014 to 2018 Paul served as Head of Chemistry at Nurix, Inc., where he built and led the Chemical Sciences department and helped develop first in class small molecules against novel E3 ligases for therapeutic use within the fields of oncology and immuno-oncology. This includes the advancement of Nurix’s small molecule Cbl-b inhibitor. He played a pivotal role in initiating Nurix’s entry into their DEL and PROTAC technology platforms, enabling a protein degradation therapeutic pipeline which includes Nurix’s BTK degrader currently in pre-clinical development. From 2006 to 2014, Paul worked at the Novartis Institutes for Biomedical Research (NIBR) where he served in various leadership roles including, Oncology Group Leader, Medicinal Chemistry where he and his teams focused on delivering best in class clinical candidates to treat cancer patients, including the RAF kinase inhibitor LHX254. Prior to Novartis, Paul worked in the fields of oncology and infectious diseases at Chiron Corporation (acquired by Novartis).

Paul is an author on over 50 publications and patents. Paul obtained both his Chemistry B.Sc. (Hons) and his Ph.D. in Organic Chemistry from the University of Bath. He completed his postdoctoral fellowship at the University of Illinois at Urbana-Champaign with Professor Scott E. Denmark.

LinkedIn

Jason S. Throne, J.D.

Chief Legal Officer

Jason has over 20 years of legal experience representing both public and private life sciences companies. He joined IDEAYA Biosciences as Vice President, General Counsel in October 2019. Prior to joining IDEAYA Biosciences, Jason served as Vice President, General Counsel of NeoTract, Inc., a urology medical device company, until its acquisition by Teleflex Incorporated. Prior to NeoTract, Jason held various roles, including Associate General Counsel, Corporate & Compliance Officer, at Thoratec Corporation (NASDAQ: THOR), a cardiology medical device company, which was acquired by St. Jude Medical. Previously, Jason was an associate at the law firm of Cooley Godward LLP, representing both private and public companies on corporate matters, and a senior audit accountant at the accounting firm of Deloitte & Touche LLP.

Jason earned a J.D. from the University of Virginia School of Law and a B.S. in Business from the University of Colorado.

LinkedIn

Andres Ruiz Briseno, C.P.A.

Senior Vice President, Head of Finance and Investor Relations

Andres has over 10 years of finance and operations experience working with public and private life science companies. Andres was previously at Pharmacyclics, Inc., (NASDAQ: PCYC) where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster cancer drug, IMBRUVICA® (ibrutinib) and played a key role in building the Company’s long-range planning and the integration activities into AbbVie, following Pharmacyclics’ $21 billion acquisition.Prior to joining Pharmacyclics, Andres held roles at Theravance, Inc. (NASDAQ: THRX), and at PricewaterhouseCoopers’ audit and assurance practice where he focused on life science and venture capital clients.

Andres obtained his B.S. in Business Administration with a concentration in Corporate Financial Management from San Jose State University and is a Certified Public Accountant, licensed in the state of California. Andres also serves as a member of the Advisory Board of Drug Hunter.

LinkedIn

Mick O’Quigley

Senior Vice President, Development Operations

Mick has over two decades of clinical research and management experience across all phases of oncology drug development. As Senior Vice President, Development Operations, Mick is responsible for the oversight and execution of IDEAYA’s clinical pipeline. Prior to joining IDEAYA, Mick served as a Program Group Director in clinical operations at Genentech’s Research and Early Development group from January 2008 to June 2018 where he was responsible for multiple cell-signaling and immuno-oncology programs. Mick led the initiation and operational implementation of a global network of leading immuno-oncology institutions to accelerate clinical research across the Roche-Genentech pipeline. Prior to joining Genentech, Mick worked at Amgen from 1996 to 2008 where he held roles of increasing clinical development responsibilities for multiple products, including Aranesp®, Kepivance® and Vectibix®. Mick also held earlier roles at Rhône-Poulenc Rorer and PAREXEL.

Mick earned his M.B.A. from Pepperdine University and his B.A. from Trinity College Dublin.

LinkedIn

Matthew Maurer, M.D.

Vice President, Late Phase Oncology Clinical Development

Matt has over 15 years of combined translational, clinical, and pharmaceutical cancer research experience. He is Vice President, Head of Medical Affairs and Clinical Oncology at IDEAYA. A graduate of Mount Sinai medical school, Matt completed a joint research internal medicine residency and clinical fellowship in hematology and oncology at Columbia University Irving Medical Center. Matt then joined the faculty at Columbia as a physician scientist and clinical breast cancer expert with a focus on developmental therapeutics and earned a masters in biostatistics from the Mailman School of Public Health patient oriented research program. Matt left academia to join the Early Clinical and Translational Research group at Bristol Myers Squibb and served as the medical lead of multiple first in human programs. Most recently, Matt served as the clinical development lead in charge of the late development portfolio of nivolumab and ipilimumab in both renal cell carcinoma and prostate cancer.

Matt obtained his undergraduate degree from Princeton University and his medical degree from Mount Sinai School of Medicine, and then completed his residency at Columbia University Medical Center.

LinkedIn

Claire L. Neilan, Ph.D., DABT

Vice President, Preclinical Sciences

Claire joined IDEAYA Biosciences in 2017 and in her current role she is responsible for the strategic direction of Nonclinical Safety and Pharmacology activities supporting IDEAYA’s portfolio of small molecules. Prior to joining IDEAYA, Claire served as a Project Toxicologist at Incyte and Gilead Sciences, where she was responsible for Nonclinical Safety for small and large molecules indicated for oncology and inflammation. Claire is also an experienced Project Team Lead and has successfully led Research teams through Discovery phase to First-in-Human. During her industry career of 2 decades, Claire has led Toxicology efforts for more than 15 INDs and has contributed to the approval of 4 drugs (Jakafi™, Olumiant™, Jyseleca™, and Opzelura™). Claire received her BSc (Hons) in Medicinal and Pharmaceutical Chemistry and PhD in Pharmacology from the University of Loughborough in the UK, and completed Postdoctoral training at the University of Michigan and Memorial Sloan Kettering Cancer Center. Claire obtained the Diplomate of the American Board of Toxicology (DABT) in 2012.

LinkedIn

Jasgit Sachdev, M.D.

Vice President, Early Phase Oncology Clinical Development

Dr. Jasgit Sachdev is a medical oncologist and physician scientist with extensive academic and industry experience in oncology drug development. In her academic career, she was an Associate Professor in the Clinical Translational Research Division at the Translational Genomic Research Institute (TGen) in Phoenix, AZ where she served as Director of the Breast and GYN Cancers Early Phase Trials Program at the HonorHealth Research Institute for close to 10 years. She has been a principal investigator on more than 70 phase 1 trials of novel agents in solid tumors that included small molecules, ADCs, immune-therapeutics, cellular therapy etc., many of which have been subsequently FDA approved for various indications. Dr. Sachdev completed her fellowship in Hematology and Oncology at the University of  Tennessee Health Science Center, where she stayed on faculty as an Assistant Professor for 4 years prior to relocating to Scottsdale in 2011. She has been actively engaged in clinical and translational research throughout her career. She served as a voting member of the National Comprehensive Cancer Network (NCCN) breast cancer panel for two years and as a member of the breast cancer working group for the SouthWest Oncology Group (SWOG). She has presented her research at national and international meetings and has published several peer
reviewed manuscripts. In 2021, she transitioned to an industry career joining Biosplice therapeutics, in San Diego, CA to lead clinical development for a small molecule CLK/DYRK inhibitor. She joined Ideaya Biosciences in June, 2023 as Vice President of Early Phase Oncology  Clinical Development and will be responsible for managing the early stage oncology portfolio.

Frank McCormick, Ph.D., FRS, DSc (Hon)

SAB Chair | Professor, University of California at San Francisco

Dr. McCormick is a Professor in the University of California, at San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center and holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Prior to joining UCSF, Frank was Founder and Chief Scientific Officer at Onyx Pharmaceuticals, building on his earlier research and leadership experiences at Cetus and Chiron. At Onyx, initiated and led drug discovery efforts that led to the approval of Sorafenib for treatment of renal cell cancer and liver cancer. Dr. McCormick has served as President of the American Association for Cancer Research (AACR) and has a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers.

Full Bio

Karlene Cimprich, Ph.D.

Professor, Stanford University School of Medicine

Karlene Cimprich, Ph.D., is a Professor of Chemical and Systems Biology at Stanford University School of Medicine. She is also a member of Stanford’s Cancer Institute and holds a courtesy appointment in the Department of Biochemistry at Stanford. Dr. Cimprich’s research focuses specifically on understanding the mechanisms by which a cell maintains genome stability in the context of DNA replication, and how dysfunction of these processes can lead to cancer and other diseases. Dr. Cimprich is a recipient of numerous awards, including the Kimmel Scholar Award, the Burroughs Wellcome New Investigator Award in Toxicology, the Leukemia and Lymphoma Society Scholar Award and the Ellison Medical Foundation Senior Scholar Award in Aging.

Trey Ideker, Ph.D.

Professor, University California at San Diego

Trey Ideker, Ph.D., is a Professor in Medicine, Bioengineering and Computer Science at UCSD; Co-Director of the Cancer Genomes and Networks Program at UCSD Moores Comprehensive Cancer Center, and Director of the San Diego Center for Systems Biology. His lab develops technology to build molecular network maps of the cell and to use these networks to translate genotype to phenotype in cancer. Dr. Ideker has founded influential bioinformatic tools including Cytoscape, a popular network analysis platform which has been cited >12,000 times. Dr. Ideker serves on the Editorial Boards for Cell, Cell Reports, Molecular Systems Biology, and PLoS Computational Biology and is a Fellow of AAAS and AIMBE. He was named one of the Top 10 Innovators of 2006 by Technology Review magazine and was the recipient of the 2009 Overton Prize from the International Society for Computational Biology.

Full Bio

Kornelia Polyak, M.D., Ph.D.

Professor, Dana-Farber Cancer Institute, Harvard Medical School

Kornelia Polyak, M.D., Ph.D., is Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a co-leader of the Dana-Farber Harvard Cancer Center Cancer Cell Biology Program. Dr. Polyak is an internationally recognized leader of breast cancer research. Her laboratory is dedicated to improving the clinical management of breast cancer patients by understanding of breast cancer risk and tumor evolution. Dr. Polyak has devoted substantial efforts to develop new ways to study tumors and to apply interdisciplinary approaches. Dr. Polyak has received numerous awards, including the Paul Marks Prize for Cancer Research, the AACR Outstanding Investigator Award for Breast Cancer Research and the 14th Rosalind E. Franklin Award for Women in Science. She is a recipient as well of the NCI Outstanding Investigator award and received a Distinguished Alumna Award from Weil-Cornell. Dr. Polyak was elected as a Fellow of the American Association for the Advancement of Science and the American Association for Cancer Research Academy in 2020, and to the National Academy of Sciences and the National Academy of Medicine in 2022. She is also a recipient of the American Cancer Society Research Professor Award.

William R. Sellers, M.D.

Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School

Dr. Sellers is a Core Institute Member at the Broad Institute and faculty member of the Dana-Farber Cancer Institute and Harvard Medical School. From 2005-2016, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for BioMedical Research, during which the oncology research group brought more than 30 cancer therapeutics into first-in-man trials including therapeutics targeting the PI3K, CDK4, IDH, ABL, SMO, HER3, ALK, Wnt, PIM and Ras pathways among others. Along with Dr. Carl June, he co-chaired the CART collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.

Prior to Novartis, Dr. Sellers was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute where he initiated large-scale projects which led to discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene. Dr. Sellers was a member of the National Cancer Advisory Board from 2011 to 2016. Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute.

Full Bio

Elizabeth Swisher, M.D.

Professor, University of Washington

Elizabeth Swisher, M.D., is a gynecologic oncologist, Professor of Gynecologic Oncology, and adjunct Professor of Medical Genetics at the University of Washington in Seattle. Dr. Swisher’s research focused on understanding the role of the BRCA-Fanconi anemia pathway in ovarian cancer and how defects in DNA repair can be exploited in the therapy and prevention of ovarian carcinoma. She is co-Leader of Stand up to Cancer’s first Ovarian Cancer Dream Team. She is principal investigator on several PARP inhibitor therapeutic trials and collaborates on the translational research for numerous other clinical trials in ovarian and other cancers.

Full Bio

Terry Rosen, Ph.D.

Chairman of the Board | Chief Executive Officer, Arcus Biosciences

Terry Rosen, Ph.D. is currently the CEO of Arcus Biosciences. He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015. Prior to co-founding Flexus in October of 2013, Dr. Rosen served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Dr. Rosen held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. He holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley.

LinkedIn

Garret Hampton, Ph.D.

Director | President, Clinical Sequencing and Oncology, ThermoFisher Scientific

Garret Hampton, Ph.D., is currently President, Clinical Sequencing and Oncology at ThermoFisher Scientific, responsible for leading the company’s clinical next generation sequencing strategy. Prior to ThermoFisher, Dr. Hampton was Senior Vice President, Clinical Genomics, at Illumina, responsible for the development of sequencing-based solutions in oncology, reproductive health and whole genome sequencing for the diagnosis of rare disease. Before joining Illumina, Dr. Hampton held a variety of leadership positions at Genentech / Roche; Celgene, and The Genomics Institute of the Novartis Research Foundation, focused on drug target discovery, drug development and precision medicine. Before moving into industry, Dr. Hampton was Assistant Professor of Medicine at UCSD, San Diego after a 2-year postdoctoral fellowship at the Salk Institute for Biological Studies. Dr. Hampton received his Ph.D. from the Imperial Cancer Research Fund (now Cancer Research UK) under Sir Walter Bodmer. He has authored over 150 peer reviewed articles and reviews, with 10,000 lifetime citations.

LinkedIn

Susan Kelley, M.D.

Director

Susan L. Kelley, M.D. most recently served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head – Oncology, where she led the team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib). Prior to joining Bayer, Dr. Kelley worked at Bristol-Myers Squibb in Oncology and Immunology drug development, ultimately serving as Executive Director, Oncology Clinical Research, at the Bristol-Myers Squibb Pharmaceutical Research Institute. She serves or has served as a member of the Board of Directors at multiple publicly traded companies including Deciphera Pharmaceuticals, Daré Bioscience, VBL Therapeutics Ltd, ArQule and Immune Design. Dr. Kelley received her M.D. from Duke University School of Medicine. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine.

LinkedIn

Catherine Mackey, Ph.D.

Director | Former Senior Vice President of Pfizer Worldwide Research and Development

Dr. Mackey has more than 30 years of experience in the pharmaceutical and biotechnology industries. Most recently she served as Senior Vice President of Pfizer Global Research and Development and Director of Pfizer's La Jolla Laboratories, where she built Pfizer La Jolla Labs into one of Pfizer's main pharmaceutical research and development sites with over 1,000 employees and a robust drug pipeline. Prior to that role, she served as head of Strategic Alliances and Genomic and Proteomic Sciences for Pfizer. Dr. Mackey spent the first part of her career in agricultural biotechnology, including as Vice President of DEKALB Genetics, Inc. Currently she is a member of the Boards of Directors of Avid Bioservices, Voyager Therapeutics, Rady Children’s Hospital and Rady Children’s Institute of Genomic Medicine. Previously, she served on the Boards of Directors of COUR, Trillium Therapeutics, Poseida Therapeutics, GW Pharma, Evolve Biosystems, Sequenom, Viventia Bio, YM Biosciences, and Althea Technologies. Dr. Mackey received her B.S. and Ph.D. degrees in microbiology from Cornell University.

LinkedIn

Scott Morrison

Director | Partner, Ernst & Young (retired)

Mr. Morrison has served as a member of IDEAYA's board of directors since July 2018. He had a 35-year career in public accounting, serving public and private companies in the life sciences sector. Mr. Morrison was a partner at Ernst & Young LLP and served as its U.S. Life Sciences Leader until his retirement in 2015. He has worked on hundreds of public and private financings, M&A transactions and corporate collaborations. Mr. Morrison currently serves on the board of directors and chairs the audit committees of Corvus Pharmaceuticals, Tarsus Pharmaceuticals, Vera Therapeutics and Zai Lab. He has served on numerous life sciences industry boards, including the Biotechnology Innovation Organization (BIO) ECS Board, the Bay Area Bioscience Center, the California Life Sciences Foundation, and the Biotechnology Institute. Mr. Morrison holds a B.S. in business administration from the University of California, Berkeley. He is a certified public accountant (inactive).

LinkedIn

Jeffrey Stein, Ph.D.

Director | President and Chief Executive Officer, Cidara Therapeutics

Jeffrey Stein, Ph.D., has been the President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.

LinkedIn

Wendy Yarno

Director | Former Executive Vice President and Chief Marketing Officer, Merck & Co.

Ms. Yarno spent 26 years at Merck & Co. in commercial and human resource positions of increasing seniority, including most recently as Executive Vice President and Chief Marketing Officer. She previously served as General Manager, Cardiovascular / Metabolic U.S. Business Unit and as Executive Vice President, Worldwide Human Health Marketing. In these roles, Ms. Yarno developed deep expertise in pharmaceutical commercialization, including drug development, regulatory strategy, market development, global product strategy and product life-cycle management. Ms. Yarno currently serves on the board of directors of publicly traded life sciences companies Inovio Pharmaceuticals, Inc. and Tarsus Pharmaceuticals. She previously served on the board of directors of various other life science companies, including Alder Biopharmaceuticals, Durata Therapeutics, Global Blood Therapeutics, St. Jude Medical, Medivation and MyoKardia.

LinkedIn

GlaxoSmithKline

IDE397 (MAT2A), Pol Theta, Werner Helicase

IDEAYA and GSK entered into a broad strategic partnership in Synthetic Lethality. The partnership covers three IDEAYA Synthetic Lethality programs – MAT2A, Pol Theta and Werner Helicase. The companies have highly complementary Synthetic Lethality pipelines that enable strategic combination opportunities.

June 2020 Announcement

Pfizer Inc.

IDEAYA and Pfizer have established a clinical trial collaboration and supply agreement, pursuant to which Pfizer will supply binimetinib, a MEK inhibitor, and crizotinib, a cMET inhibitor, in support of an ongoing IDEAYA-sponsored Phase 1/2 clinical trial evaluating IDE196 in combination with binimetinib, and in a separate arm of the clinical trial, in combination with crizotinib, in each case in patients harboring GNAQ or GNA11 mutated solid tumors, including in metastatic uveal melanoma.

March 2020 Announcement
September 2020 Announcement

Amgen Inc.

IDEAYA and Amgen have established a clinical trial collaboration and supply agreement, pursuant to which, we plan to evaluate IDE397 in combination with AMG 193, the Amgen investigational methylthioadenosine-, or MTA-cooperative protein arginine methyltransferase 5, or PRMT5, inhibitor, in patients having tumors with MTAP deletion, in an Amgen-sponsored Phase 1/2 clinical trial.

Cancer Research UK / University of Manchester

IDEAYA has established a strategic research collaboration with the Drug Discovery Unit at Cancer Research UK (CRUK) and the University of Manchester related to IDEAYA’s Poly(ADP-ribose) glycohydrolase (PARG) program. IDEAYA controls all commercial rights in its PARG program.

March 2020 Announcement

University of California San Diego

Synthetic Lethality Target Identification

IDEAYA is collaborating with Dr. Trey Ideker PhD, Professor of Medicine and Bioengineering, UCSD, on combinatorial CRISPR screens of key nodes of the DNA damage and repair pathway and human tumor suppressor genes to identify next generation synthetic lethality targets.

Broad Institute

Biomarker and Translational Research

IDEAYA is member of the Broad Institute’s DepMap Consortium, enabling access to genome-wide screens of cell lines based on single CRISPR gene editing. We are also collaborating with Dr. Bill Sellers, M.D., a core institute member of the Broad Institute, and faculty member at Harvard Medical School and at Dana-Farber Cancer Institute. Our collaborative research aims are directed to identifying and validating synthetic relationships, including through the Broad’s dual sgRNA knock-down paralog screens to identify targets having functional redundancies.

October 2020 Announcement

University of California San Francisco

Biomarker and Translational Research

IDEAYA is engaged in collaborative research with Dr. Sourav Bandyopadhyay, PhD, an Associate Professor in the Department of Bioengineering and Therapeutic Sciences of the Helen Diller Family Comprehensive Cancer Center at UCSF, to identify and validate biomarker-enabled synthetic lethal relationships.

Novartis Institute for Biomedical Research (NIBR)

IDE196 (PKC)

IDEAYA has an exclusive license with Novartis International Pharmaceutical Ltd. pursuant to which IDEAYA is developing and commercializing IDE196, a potent, small molecule protein kinase C (PKC) inhibitor for the treatment of cancers having GNAQ and GNA11 mutations. IDEAYA controls all commercial rights in its PKC program.

October 2018 Announcement